Cargando…

Reactive oxygen species levels control NF-κB activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes

Anemia is a frequent cytopenia in myelodysplastic syndromes (MDS) and most patients require red blood cell transfusion resulting in iron overload (IO). Deferasirox (DFX) has become the standard treatment of IO in MDS and it displays positive effects on erythropoiesis. In low risk MDS samples, mechan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meunier, Mathieu, Ancelet, Sarah, Lefebvre, Christine, Arnaud, Josiane, Garrel, Catherine, Pezet, Mylène, Wang, Yan, Faure, Patrice, Szymanski, Gautier, Duployez, Nicolas, Preudhomme, Claude, Biard, Denis, Polack, Benoit, Cahn, Jean-Yves, Moulis, Jean Marc, Park, Sophie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739655/ https://www.ncbi.nlm.nih.gov/pubmed/29285268 http://dx.doi.org/10.18632/oncotarget.22299

Ejemplares similares

Molecular dissection of engraftment in a xenograft model of myelodysplastic syndromes
por: Meunier, Mathieu, et al.
Publicado: (2018)

Transfusion-dependent low-risk myelodysplastic patients receiving deferasirox: Long-term follow-up
por: IMPROTA, SALVATORE, et al.
Publicado: (2013)

Modulation of the Immune Response by Deferasirox in Myelodysplastic Syndrome Patients
por: Votavova, Hana, et al.
Publicado: (2021)

Deferasirox-induced urticarial vasculitis in a patient with myelodysplastic syndrome
por: Polat, Asude Kara, et al.
Publicado: (2017)

Protein Carbonylation in Patients with Myelodysplastic Syndrome: An Opportunity for Deferasirox Therapy
por: Rodríguez-García, Alba, et al.
Publicado: (2019)

Ferritin level changes and erythroid improvement in a group of adult polytransfused patients treated with Deferasirox
por: PARVU, ANDRADA VIORICA, et al.
Publicado: (2018)

An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome
por: Ebert, Benjamin L, et al.
Publicado: (2008)

Disruption of erythroid nuclear opening and histone release in myelodysplastic syndromes
por: Zhao, Baobing, et al.
Publicado: (2019)

Myelodysplastic Syndrome with Erythroid Aplasia following Pure Red Cell Aplasia
por: Kim, Hyoung Doo, et al.
Publicado: (2004)

Hypersensitivity reaction with deferasirox
por: Sharma, Atul, et al.
Publicado: (2015)

A Case of Relapsing Polychondritis Associated with Myelodysplastic Syndrome with Erythroid Hypoplasia/Aplasia
por: Heo, Seong-Wook, et al.
Publicado: (2003)

Impaired Mitophagy of Nucleated Erythroid Cells Leads to Anemia in Patients with Myelodysplastic Syndromes
por: Jiang, Huijuan, et al.
Publicado: (2018)

Low oxygen tension reverses antineoplastic effect of iron chelator deferasirox in human glioblastoma cells
por: Legendre, Claire, et al.
Publicado: (2016)

A 17-gene-expression profile to improve prognosis prediction in childhood acute myeloid leukemia
por: Duployez, Nicolas, et al.
Publicado: (2018)

High expression of APAF-1 elevates erythroid apoptosis in iron overload myelodysplastic syndrome
por: Gu, Shucheng, et al.
Publicado: (2013)

A three-dimensional in vitro model of erythropoiesis recapitulates erythroid failure in myelodysplastic syndromes
por: Elvarsdóttir, Edda María, et al.
Publicado: (2019)

Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study
por: Porter, John, et al.
Publicado: (2008)

Deferasirox: Duodenal perforation: case report
Publicado: (2021)

Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload
por: Wu, Dijiong, et al.
Publicado: (2018)

Population Pharmacokinetics and Exposure–Response of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With Myelodysplastic Syndromes
por: Chen, Nianhang, et al.
Publicado: (2020)

Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy
por: Porter, J. B., et al.
Publicado: (2012)

Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox
por: Taher, Ali T, et al.
Publicado: (2014)

Update on the use of deferasirox in the management of iron overload
por: Taher, Ali, et al.
Publicado: (2009)

Pharmacogenetic Study of Deferasirox, an Iron Chelating Agent
por: Lee, Ji Won, et al.
Publicado: (2013)

Deferasirox: Over a Decade of Experience in Thalassemia
por: Moukalled, Nour M., et al.
Publicado: (2018)

Deferasirox – a rarer cause of Fanconi syndrome
por: Khan, Iman, et al.
Publicado: (2019)

Synthesis and Study of Multifunctional Cyclodextrin–Deferasirox Hybrids
por: Gascon, Jose Miguel, et al.
Publicado: (2019)

Evaluation of Pharmacokinetics and Pharmacodynamics of Deferasirox in Pediatric Patients
por: Galeotti, Laura, et al.
Publicado: (2021)

Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange
por: Gattermann, Norbert, et al.
Publicado: (2012)

A New Patient-Derived Metastatic Glioblastoma Cell Line: Characterisation and Response to Sodium Selenite Anticancer Agent
por: Berthier, Sylvie, et al.
Publicado: (2018)

Past, present and future in low-risk myelodysplastic syndrome
por: Toprak, Selami Kocak
Publicado: (2022)

Increased Apoptotic Activity in Low-Risk Myelodysplastic Syndrome
por: Park, Songyi, et al.
Publicado: (2022)

Deferasirox Reduces Oxidative Stress in Patients With Transfusion Dependency
por: Saigo, Katsuyasu, et al.
Publicado: (2013)

Deferasirox: appraisal of safety and efficacy in long-term therapy
por: Chaudhary, Preeti, et al.
Publicado: (2013)

Pharmacological and clinical evaluation of deferasirox formulations for treatment tailoring
por: Piolatto, Andrea, et al.
Publicado: (2021)

Effects of Deferasirox in Alzheimer’s Disease and Tauopathy Animal Models
por: Kwan, Ping, et al.
Publicado: (2022)

Deferasirox Nanosuspension Loaded Dissolving Microneedles for Intradermal Delivery
por: Faizi, Hafsa Shahid, et al.
Publicado: (2022)

Flow cytometry lyophilised-reagent tube for quantifying peripheral blood neutrophil myeloperoxidase expression in myelodysplastic syndromes (MPO-MDS-Develop): protocol for a diagnostic accuracy study
por: Raskovalova, Tatiana, et al.
Publicado: (2022)

P736: ANALYSIS OF RESPONSE RATES AND OUTCOMES IN ERYTHROID-PREDOMINANT MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH VENETOCLAX-BASED REGIMENS
por: Bazinet, Alexandre, et al.
Publicado: (2023)

Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in β-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial
por: Porter, John, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_3or6p2a5ch2j9djvp92mbmvg8v